Suspect Iron Deficiency in HF
mobile treatment banner

DISCOVER THE RIGHT TREATMENT
FOR YOUR PATIENTS

treatment mobile cloud left 1 treatment mobile cloud right 1 treatment mobile cloud left 2 treatment mobile cloud right 2 treatment desktop cloud right 1 treatment desktop cloud right 2 treatment desktop cloud right 3 treatment desktopt cloud left 1

In patients with heart failure (HF) and iron deficiency (ID) with or without anemia, consider intravenous (IV) iron1,2

Treatment of iron deficiency with or without anemia should be considered given its high prevalence in patients with chronic and acute HF.2

Treatment goals for iron deficiency in patients with HF include:

  • TARGETING FERRITIN LEVELS ABOVE 100 μg/L ALONG WITH TRANSFERRIN SATURATION (TSAT) >20%1
  • POTENTIALLY REVERSING THE NEGATIVE EFFECTS OF ID ON CARDIAC MUSCLE AND IMPROVING OVERALL CONTRACTILITY AND EJECTION FRACTION (EF)3

While iron deficiency may negatively affect cardiomyocytes and their contractility, intracellular iron restoration may reverse this damage and lead to significant improvement in left ventricular (LV) function.3

Oral iron is not adequate1,4

Oral iron therapy was not proven to be effective in iron repletion and did not improve exercise capacity for the treatment of iron deficiency in patients with HF with reduced ejection fraction (HFrEF).1,4

IV iron can be effective1

2022 AHA/ACC/HFSA GUIDELINES SPOTLIGHT

Intravenous (IV) iron is a class 2a recommendation to treat patients with HFrEF and iron deficiency with or without anemia as it has been shown to improve functional status and quality of life (QoL).1

How your patients with HF and iron deficiency may benefit from an IV iron treatment:

  • May reverse iron deficiency induced cardiac remodeling and improve left ventricular ejection fraction (LVEF).3
  • Even in healthy patients, less than 10% of oral iron is absorbed.5* With IV iron, 100% of iron is delivered into the bloodstream.
  • IV iron therapy may help improve QoL.6,7

*A typical dose is a 300-mg ferrous sulfate tablet or 320-mg ferrous gluconate tablets (taken 3 to 4 times daily). Approximately 10% of oral iron is absorbed.5

THE IMPACT OF AN IV IRON TREATMENT CAN BE OBVIOUS
treatment mobile cloud left 3 treatment mobile cloud right 3

Higher-dose, well-studied IV iron preparations with proven efficacy have the potential to replete iron stores faster, reduce medical visits, and reduce unnecessary fluid infusions.8-10

treatment mobile cloud left 4 treatment mobile cloud right 4 treatment mobile cloud left 5 treatment mobile cloud rightt 5

Discover a treatment option

  • An IV iron is available for certain patients with HF and iron deficiency.
Click here to learn more

Identify and treat iron deficiency before it worsens to anemia

  • The clinical benefits of treating iron deficiency outweigh the additional damage that may be done from waiting for it to worsen to IDA8
  • Reduced oxygen delivery to metabolizing tissues in anemic patients may trigger a host of hemodynamic alterations including low arterial blood pressure which may worsen HF in some patients8
  • In patients with HF, anemia may double the risk of death and when adjusted, may increase the risk of death by 1.5 fold when paired with chronic kidney disease (CKD)8
Go to: Resources
References: 1. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):e263-e421. doi.org/10.1016/j.jacc.2021.12.012 2. von Haehling S, Ebner N, Evertz R, et al. Iron deficiency in heart failure: An overview. JACC Heart Fail. 2019;7(1):36-46. doi:10.1016/j.jchf.2018.07.015 3. López-Vilella R, Lozano-Edo S, Arenas Martin P, et al. Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction. ESC Heart Fail. 2022;9(1):133-145. doi:10.1002/ehf2.13753 4. Lewis GD, Molhotra R, Hernandez AF, et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency the IRONOUT HF randomized clinical trial. JAMA. 2017;317(19):1958-1966. doi:10.1001/jama.2017.5427 5. Zhu A, Kaneshiro M, Kaunitz JD. Evaluation and treatment of iron deficiency anemia: a gastroenterological perspective. Dig Dis Sci. 2010;55(3):548-559. doi:10.1007/s10620-009-1108-6 6. Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(4):575-582.e3. doi:10.1016/j.ahj.2013.01.017 7. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36(11):657-668. doi:10.1093/eurheartj/ehu385 8. Anand IS, Gupta P. Anemia and iron deficiency in heart failure: current concepts and emerging therapies. Circulation. 2018;138(1):80-98. doi:10.1161/CIRCULATIONAHA.118.030099 9. Beverina I, Razionale G, Ranzini M, et al. Early intravenous iron administration in the emergency department reduces red blood cell unit transfusion, hospitalisation, re-transfusion, length of stay and costs. Blood Transfus. 2020;18(2):106-116. doi:10.2450/2019.0248-19 10. LaVallee C, Bansal I, Kamdar S, et al. Relationship between initial parenteral iron therapy dosing and treatment effectiveness: a real-world retrospective analysis. J Blood Med. 2022;13:133-142. doi:10.2147/JBM.S349070